JP2014528699A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528699A5
JP2014528699A5 JP2014521612A JP2014521612A JP2014528699A5 JP 2014528699 A5 JP2014528699 A5 JP 2014528699A5 JP 2014521612 A JP2014521612 A JP 2014521612A JP 2014521612 A JP2014521612 A JP 2014521612A JP 2014528699 A5 JP2014528699 A5 JP 2014528699A5
Authority
JP
Japan
Prior art keywords
felv
composition
seq
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014521612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528699A (ja
JP6084970B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/023658 external-priority patent/WO2013012446A1/en
Publication of JP2014528699A publication Critical patent/JP2014528699A/ja
Publication of JP2014528699A5 publication Critical patent/JP2014528699A5/ja
Application granted granted Critical
Publication of JP6084970B2 publication Critical patent/JP6084970B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014521612A 2011-07-20 2012-02-02 最適化ネコ白血病ウイルスエンベロープ遺伝子を含む組換えネコ白血病ウイルスワクチン Active JP6084970B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509912P 2011-07-20 2011-07-20
US61/509,912 2011-07-20
PCT/US2012/023658 WO2013012446A1 (en) 2011-07-20 2012-02-02 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016212839A Division JP6240294B2 (ja) 2011-07-20 2016-10-31 最適化ネコ白血病ウイルスエンベロープ遺伝子を含む組換えネコ白血病ウイルスワクチン

Publications (3)

Publication Number Publication Date
JP2014528699A JP2014528699A (ja) 2014-10-30
JP2014528699A5 true JP2014528699A5 (enExample) 2015-01-08
JP6084970B2 JP6084970B2 (ja) 2017-02-22

Family

ID=45722710

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014521612A Active JP6084970B2 (ja) 2011-07-20 2012-02-02 最適化ネコ白血病ウイルスエンベロープ遺伝子を含む組換えネコ白血病ウイルスワクチン
JP2016212839A Active JP6240294B2 (ja) 2011-07-20 2016-10-31 最適化ネコ白血病ウイルスエンベロープ遺伝子を含む組換えネコ白血病ウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016212839A Active JP6240294B2 (ja) 2011-07-20 2016-10-31 最適化ネコ白血病ウイルスエンベロープ遺伝子を含む組換えネコ白血病ウイルスワクチン

Country Status (25)

Country Link
US (2) US8895027B2 (enExample)
EP (1) EP2734230B1 (enExample)
JP (2) JP6084970B2 (enExample)
CN (1) CN103957932B (enExample)
AU (2) AU2012284558B2 (enExample)
BR (1) BR112014001287B1 (enExample)
CA (1) CA2842055C (enExample)
CY (1) CY1125328T1 (enExample)
DK (1) DK2734230T3 (enExample)
ES (1) ES2720150T3 (enExample)
HR (1) HRP20190271T1 (enExample)
HU (1) HUE043547T2 (enExample)
IL (1) IL230460B (enExample)
IN (1) IN2014CN00547A (enExample)
LT (1) LT2734230T (enExample)
MX (1) MX351642B (enExample)
PL (1) PL2734230T3 (enExample)
PT (1) PT2734230T (enExample)
RS (1) RS58289B1 (enExample)
RU (1) RU2591817C2 (enExample)
SI (1) SI2734230T1 (enExample)
SM (1) SMT201900129T1 (enExample)
TR (1) TR201901466T4 (enExample)
WO (1) WO2013012446A1 (enExample)
ZA (1) ZA201400349B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2019068905A2 (en) * 2017-10-06 2019-04-11 Virbac Feline vaccines conferring early protection
CN111848785B (zh) * 2020-07-10 2022-09-06 青岛博隆基因工程有限公司 猫疱疹病毒抗体序列、四肽链分子、免疫球蛋白分子

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
NZ221790A (en) 1986-09-12 1990-07-26 Genentech Inc Method for the continuous production of a heterologous protein in a eukaryotic host cell
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
ES2084596T3 (es) * 1988-12-13 1996-05-16 Harvard College Materiales aislados de felv prototipos para uso en modelos de enfermedades y vacunas.
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
TR200200797T2 (tr) 1999-09-25 2002-10-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
AU2002365202A1 (en) 2001-11-09 2003-09-02 Entremed, Inc. Synthetic genes for malarial proteins and methods of use
WO2004024027A2 (en) 2002-06-07 2004-03-25 University Of Florida Endodontic files made using bulk metallic glasses
EP1553977B1 (de) * 2002-09-23 2006-08-09 Mologen AG Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
MXPA06011272A (es) 2004-03-30 2007-04-17 Roussy Inst Gustave Secuencia de polipeptidos involucrada en la modulacion del efecto inmunosupresor de las proteinas virales.
US7582302B2 (en) 2004-06-04 2009-09-01 Merial Limited Needle-free administration of FeLV vaccines
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
EP1954308B1 (en) * 2005-09-16 2011-09-07 Merial Ltd. Stabilizers for freeze-dried vaccines
CN101849013A (zh) * 2007-05-30 2010-09-29 惠氏有限责任公司 猫抗原的浣熊痘病毒表达基因

Similar Documents

Publication Publication Date Title
ES2839880T3 (es) Vacuna contra el VRS
JP2008530245A5 (enExample)
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
HRP20211566T1 (hr) Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe
JP2015096070A5 (enExample)
MX2020003176A (es) Variantes de capsides de virus adenoasociados y metodos de uso de estas.
RU2015155821A (ru) Вакцины против малярии
JP2013507907A5 (enExample)
EA201990718A1 (ru) Векторы аденовируса собачьих
JP2015501840A5 (enExample)
JP2010500399A5 (enExample)
FI3872085T3 (fi) Esimuotoiset virussekvenssit ja niiden käytöt
HRP20130022T1 (hr) Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora
RU2014135053A (ru) Иммуногены для вакцинации против вич
JP2015186478A5 (enExample)
JP2009544333A5 (enExample)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
RU2021109510A (ru) Вакцинация с использованием альфа 3 домена mica/b для лечения рака
RU2019113989A (ru) Лекарственное средство
JP2014528699A5 (enExample)
JP2016520534A5 (enExample)
JP2019505567A5 (enExample)
JP2018501258A5 (enExample)
WO2020152318A3 (en) High growth influenza virus
BR112018073454A2 (pt) vacinas